Brexanolone

Zulresso (brexanolone) is a small molecule pharmaceutical. Brexanolone was first approved as Zulresso on 2019-06-17. It is used to treat postpartum depression in the USA. It is known to target gamma-aminobutyric acid receptor subunit alpha-5, gamma-aminobutyric acid receptor subunit alpha-1, gamma-aminobutyric acid receptor subunit alpha-2, gamma-aminobutyric acid receptor subunit alpha-3, gamma-aminobutyric acid receptor subunit alpha-4, and gamma-aminobutyric acid receptor subunit alpha-6. Zulresso's patents are valid until 2037-03-08 (FDA).